source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
InvestorPlace | 2022-04-28 10:49:21 | https://investorplace.com/2022/04/7-a-rated-dividend-stocks-to-buy-forever/ | Whether in a bull market, bear market, or something in-between, make these seven high-quality dividend stocks long-term portfolio holdings. The post 7 A-Rated Dividend Stocks to Buy Forever appeared first on InvestorPlace. | 7 A-Rated Dividend Stocks to Buy Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-04-28 07:15:16 | https://247wallst.com/investing/2022/04/28/7-strong-buy-dividend-kings-to-move-to-fast-in-case-of-total-market-meltdown/ | At 24/7 Wall St., we know how important dividend size, stability and growth are to growth and income investors who need a dependable stream of income. | 7 ‘Strong Buy' Dividend Kings to Move to Fast in Case of Total Market Meltdown | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-04-27 12:03:20 | https://247wallst.com/investing/2022/04/27/earnings-previews-abbvie-astrazeneca-bristol-meyers-squibb/ | Between the time markets closed on Tuesday and before they opened again on Wednesday, more than 600 U.S. | Earnings Previews: AbbVie, AstraZeneca, Bristol-Meyers Squibb | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-04-27 08:35:00 | https://seekingalpha.com/article/4503783-abbvie-stock-what-to-know-upcoming-earnings | AbbVie is set to report highly-anticipated earnings this week. The stock has been terrific this year, buoying many portfolios while other sectors have suffered. | AbbVie Stock: What To Know Ahead Of Upcoming Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-26 12:47:19 | https://www.zacks.com/stock/news/1907964/healthcare-etfs-in-focus-ahead-of-q1-earnings | The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio. | Healthcare ETFs in Focus Ahead of Q1 Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-04-26 07:36:17 | https://investorplace.com/2022/04/7-retirement-stocks-to-buy-to-sleep-soundly-at-night-kmb-lmt-mrk-abbv-dlr-gis-pg/ | As the population ages, more people are looking for ways to save for retirement. This can be done by investing in retirement stocks. | 7 Retirement Stocks to Buy to Sleep Soundly at Night | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-04-26 06:30:18 | https://investorplace.com/2022/04/recession-stocks-to-buy-that-will-do-well-in-a-recession-our-7-top-picks-mcd-tgt-wmt-pg-abbv-mgn-nrg/ | Americans will still use brand names, buy groceries and clothes, get healthcare services and pay their utilities during a recession. That's good news for these 7 recession-resistant stocks to buy. | What Stocks to Buy That Should Do Well in a Recession — Our 7 Top Picks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-25 05:52:00 | https://www.fool.com/investing/2022/04/25/3-warren-buffett-dividend-stocks-you-can-buy-right/ | They're not good picks just because of their dividends. | 3 Warren Buffett Dividend Stocks You Can Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-24 05:52:00 | https://www.fool.com/investing/2022/04/24/dividend-stocks-trouncing-the-market-are-they-buys/ | Investors don't like these stocks only because of their dividends. | These Dividend Stocks Are Trouncing the Market -- Are They Still Buys? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-24 05:00:00 | https://www.fool.com/investing/2022/04/24/dividend-growth-titans-increase-passive-income/ | There's nothing quite like a growing dividend to help you cover your costs when inflation rears its ugly head. | 3 Dividend Growth Titans to Increase Your Passive Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-23 06:08:00 | https://www.fool.com/investing/2022/04/23/3-dividend-stocks-you-can-buy-and-hold-for-decades/ | Each of these companies has a long history of success. | 3 Dividend Stocks You Can Buy and Hold for Decades | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-22 16:33:13 | https://www.zacks.com/stock/news/1905635/abbvie-abbv-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release | AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-04-21 17:57:26 | https://www.gurufocus.com/news/1692339/abbvie-and-bayer-record-hefty-share-price-gains-in-1st-quarter | Two health care companies most investors might not be familiar with were among the four biggest stock market gainers in the first quarter, according to an analysis by Evaluate. | AbbVie and Bayer Record Hefty Share Price Gains in 1st Quarter | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-20 06:40:00 | https://www.fool.com/investing/2022/04/20/abbvie-snags-another-regulatory-approval-for-this/ | The company's immunology drug Rinvoq was given the go-ahead to treat adult patients with moderate-to-severe ulcerative colitis. | AbbVie Snags Another Regulatory Approval for This Blockbuster Drug | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-18 07:20:00 | https://www.fool.com/investing/2022/04/18/this-high-yielding-dividend-stock-has-raised-its-p/ | Can AbbVie continue to raise its payouts at this impressive rate in the future? | This High-Yielding Dividend Stock Has Raised Its Payout by 120% in Just 5 Years | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-04-18 07:04:38 | https://seekingalpha.com/article/4501859-preparing-for-abbvies-earnings-report-on-april-29 | AbbVie is a long-term holding that I pushed hard over the last year. AbbVie may have set a top, but this could also be a short-term resistance point, depending upon the next few weeks. AbbVie must soon contend with its recent high. | Preparing For AbbVie's Earnings Report On April 29 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-15 11:45:00 | https://www.fool.com/investing/2022/04/15/3-top-dividend-kings-to-buy-for-the-long-haul/ | These three companies bring more to the table than an ever-increasing dividend. | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-04-14 15:03:02 | https://www.benzinga.com/trading-ideas/long-ideas/22/04/26634190/7-warren-buffett-dividend-stocks-with-the-highest-yields | The stock market rally has run out of steam so far in 2022 as investors grow increasingly concerned about elevated inflation and the potential for aggressive Federal Reserve interest rate hikes. The U.S. economic outlook is uncertain, the war in Ukraine is uncertain and the valuation of growth. | 7 Warren Buffett Dividend Stocks With The Highest Yields | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-04-14 13:50:44 | https://stockmarket.com/featured/best-biotech-stocks-to-buy-now-5-to-know-2022-04-14 | Check out these biotech stocks with exciting developments today. | Best Biotech Stocks To Buy Now? 5 To Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-14 10:33:09 | https://www.zacks.com/stock/news/1899418/is-trending-stock-abbvie-inc-abbv-a-buy-now | AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2022-04-12 14:00:39 | https://marijuanastocks.com/looking-for-long-term-cannabis-stocks-to-buy-top-marijuana-stocks-to-invest-in-2022/ | Top Medical Marijuana Stocks To Invest In For 2022 The post Looking For Long Term Cannabis Stocks To Buy? Top Marijuana Stocks To Invest In 2022 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Looking For Long Term Cannabis Stocks To Buy? Top Marijuana Stocks To Invest In 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-11 13:33:15 | https://www.zacks.com/stock/news/1897117/can-abbvie-abbv-keep-the-earnings-surprise-streak-alive | AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. | Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2022-04-11 07:00:55 | https://www.forbes.com/sites/greatspeculations/2022/04/11/will-abbvie-stock-continue-to-make-new-highs/ | The price of AbbVie stock (NYSE: ABBV) reached its all-time high of around $174 yesterday. It is up over 12% in a month, while it rose a stellar 63% over the last twelve months. | Will AbbVie Stock Continue To Make New Highs? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-10 06:08:00 | https://www.fool.com/investing/2022/04/10/3-no-brainer-warren-buffett-stocks-to-buy-right-no/ | These stocks are well-positioned for today's market dynamics. | 3 No-Brainer Warren Buffett Stocks to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-09 07:31:00 | https://www.fool.com/investing/2022/04/09/3-safe-stocks-to-buy-in-an-uncertain-market/ | Their solid underlying businesses and dividends make these stocks more secure than most. | 3 Safe Stocks to Buy in an Uncertain Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-04-09 01:34:57 | https://seekingalpha.com/article/4500548-abbvie-top-stock-to-own | 100% technical buy signals. | AbbVie Top Stock To Own | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-04-08 14:51:02 | https://www.benzinga.com/trading-ideas/long-ideas/22/04/26547362/10-stocks-that-have-moved-over-20-since-the-indices-lost-over-12 | The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March. | 10 Stocks That Have Moved Over 20% Since The Indices Lost Over 12%! | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-04-08 07:35:39 | https://investorplace.com/2022/04/best-stocks-for-2022-up-20-this-year-abbv-stock-is-doing-great/ | AbbVie is great for dividend investors, and it's great for people looking for growth in 2022. The company's guidance for 2022 is exciting. | Best Stocks for 2022: Up 20% This Year, AbbVie Is Doing Great | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-04-08 05:50:08 | https://seekingalpha.com/article/4500403-johnson-and-johnson-vs-abbvie-hold | Both Johnson & Johnson and AbbVie are excellent candidates for our barbell strategy to build an enduring portfolio for earlier retirement. | Johnson & Johnson Vs. AbbVie: Why We Hold AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-07 18:49:15 | https://www.zacks.com/stock/news/1895093/2-great-dividend-stocks-to-buy-now-to-help-tackle-inflation | Investors might want to remain in stocks in order to beat 8% inflation, while adding strong dividend yields that top U.S. Treasuries. Here are few stocks to consider buying to do just that. | 2 Great Dividend Stocks to Buy Now to Help Tackle Inflation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-04-05 18:17:17 | https://investorplace.com/2022/04/7-safe-stocks-to-buy-to-guard-against-a-recession/ | It's not too late to buy safe stocks. These seven stocks, all A-rated, are perfect plays for riding out continued volatility in the markets. | 7 Safe Stocks to Buy to Guard Against a Recession | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-04-05 14:10:17 | https://www.youtube.com/watch?v=sGPbSJ0YpUQ | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: CVS, AbbVie, Walgreens & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-04-04 15:19:04 | https://www.benzinga.com/general/biotech/22/04/26457088/west-virginia-says-j-j-teva-abbvie-caused-tsunami-of-opioid-addiction-reuters | West Virginia's attorney general urged a judge to hold Johnson & Johnson (NYSE: JNJ), Teva Pharmaceuticals Industries Ltd (NYSE: TEVA), and AbbVie Inc's (NYSE: ABBV) Allergen accountable for causing a "tsunami" of opioid addiction in the. | West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-04-04 14:05:40 | https://www.youtube.com/watch?v=wWL2rHKh1eE | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: CVS, AbbVie, Delta Air Lines & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
ETF Trends | 2022-04-04 13:15:54 | https://www.etftrends.com/nasdaq-portfolio-solutions-channel/this-healthcare-etf-has-compelling-prognosis/ | Broadly speaking, the healthcare sector isn't on fire this year, but analysts are increasingly bullish on the group, citing attractive quality and valuation traits, among other factors. While the sector isn't yet ablaze in 2022, some big names in the group are delivering for investors, underscoring the point that quali... | This Healthcare ETF Has Compelling Prognosis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-03 07:03:00 | https://www.fool.com/investing/2022/04/03/3-dividend-aristocrats-to-buy-in-april/ | Unlike many Dividend Aristocrats, these stocks aren't overrated. | 3 Dividend Aristocrats to Buy in April | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Barrons | 2022-04-01 19:36:00 | https://www.barrons.com/articles/stocks-for-the-recession-that-mayor-may-notbe-coming-51648856161 | Going to cash ignores the fact that inflation is eroding the value of money as we speak. Another option: Buy the stocks that have historically performed best during recessions. | AbbVie, Exelon, and More Stocks for the Recession That May—or May Not—Be Coming | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-31 10:32:08 | https://www.zacks.com/stock/news/1890309/is-most-watched-stock-abbvie-inc-abbv-worth-betting-on-now | Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. | Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-03-30 10:30:00 | https://www.fool.com/investing/2022/03/30/3-unstoppable-stocks-to-buy-in-a-bear-market/ | Investors in these companies can sleep well at night thanks to their excellent financial health, bear market or not. | 3 Unstoppable Stocks to Buy in a Bear Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-03-30 06:11:11 | https://investorplace.com/2022/03/7-blue-chip-stocks-with-dividends-to-add-to-your-buy-list-pfejpmintcpeplmt-abbv-cvx/ | Fed rate hikes have investors looking to reduce market risk and find consistent shareholder value. These blue-chip stocks offer robust dividend yields with a consistent record of payouts. | 7 Blue-Chip Stocks With Dividends to Add to Your Buy List | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-03-28 05:52:00 | https://www.fool.com/investing/2022/03/28/3-warren-buffett-stocks-id-buy-without-any-hesitat/ | These stocks offer a lot to like. | 3 Warren Buffett Stocks I'd Buy Without Any Hesitation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-03-27 06:58:22 | https://seekingalpha.com/article/4498008-iga-deep-discount-8-25-percent-distribution-yield | IGA: Deep Discount, 8.25% Distribution Yield | IGA: Deep Discount, 8.25% Distribution Yield | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-03-26 11:37:00 | https://www.fool.com/investing/2022/03/26/have-1000-2-warren-buffett-stocks-to-buy/ | Through up and down markets, compounding dividends can be a game-changer for long-term investors. | Have $1,000? 2 Warren Buffett Stocks to Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-24 08:17:07 | https://www.zacks.com/stock/news/1886691/2-surging-stocks-to-buy-to-fight-market-volatility | Here are a couple strong, dividend-paying stocks to consider buying amid the current economic uncertainty and market volatility. | 2 Surging Stocks to Buy to Fight Market Volatility | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Invezz | 2022-03-23 16:17:05 | https://invezz.com/news/2022/03/23/abbvie-stock-is-up-20-ytd-is-it-out-of-juice-now/ | AbbVie Inc (NYSE: ABBV) is already up about 20% for the year but Boston Private's Shannon Saccocia continues to see more upside in 2022. AbbVie is a great way to play the healthcare space Saccocia is bullish on the healthcare space at large and sees ABBV as the way to play it. | AbbVie stock is up 20% YTD: is it out of juice now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-03-23 14:07:45 | https://www.youtube.com/watch?v=l6FkEdIgabU | The "Halftime Report" traders answer your questions in #AskHalftime | What's in store for Abbvie this year? #AskHalftime | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-03-22 07:36:00 | https://www.fool.com/investing/2022/03/22/is-abbvie-stock-a-buy-now/ | The drugmaker's business looks as healthy as ever. | Is AbbVie Stock a Buy Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-03-20 08:03:00 | https://www.fool.com/investing/2022/03/20/3-dividend-stocks-that-wed-buy-without-any-hesitat/ | They all have attractive dividends and solid businesses. | 3 Dividend Stocks That We'd Buy Without Any Hesitation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-03-18 16:05:02 | https://stockmarket.com/featured/3-top-health-care-stocks-to-watch-right-now-2022-03-18 | These health care stocks could be worth a look as the stock market moves sideways. | 3 Top Health Care Stocks To Watch Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-03-18 14:38:55 | https://investorplace.com/2022/03/3-dividend-growth-stocks-to-buy-during-this-market-correction/ | These dividend growth stocks may not wow you with their yields, but they can back those yields up with rising stock prices. The post 3 Dividend Growth Stocks to Buy During This Market Correction appeared first on InvestorPlace. | 3 Dividend Growth Stocks to Buy During This Market Correction | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-03-18 07:26:21 | https://247wallst.com/investing/2022/03/18/fund-managers-pile-into-big-dividend-health-care-stocks-8-strong-buy-winners/ | To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been. | Fund Managers Pile Into Big Dividend Health Care Stocks: 8 ‘Strong Buy' Winners | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-16 18:48:12 | https://www.zacks.com/stock/news/1883134/abbvie-abbv-gains-but-lags-market-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $156.05, moving +0.11% from the previous trading session. | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-16 12:47:07 | https://www.zacks.com/stock/news/1882954/abbvie-abbv-inks-deal-to-develop-covid-antiviral-treatment | AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19. | AbbVie (ABBV) Inks Deal to Develop COVID Antiviral Treatment | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-03-15 23:02:57 | https://seekingalpha.com/article/4495797-virtus-joet-etf-promising-strategy-yet-prove-itself | JOET: This Promising Strategy Has Yet To Prove Itself | JOET: This Promising Strategy Has Yet To Prove Itself | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-03-15 13:02:42 | https://investorplace.com/2022/03/3-top-stock-trades-for-this-week/ | Bulls seeking stock trades should focus on relative strength. Here are three stocks itching for new highs as the market sinks. | 3 Top Stock Trades for This Week | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-03-14 14:03:50 | https://seekingalpha.com/article/4495346-abbvie-no-longer-a-one-trick-pony | Abbvie has been a one trick pony that relied heavily on a single drug, Humira, in the past. However, management has been actively expanding the portfolio. | AbbVie: No Longer A One Trick Pony | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-14 12:02:03 | https://www.zacks.com/stock/news/1881674/abbvie-abbv-inks-deal-for-neuropsychiatric-conditions | AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar. | AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-11 12:48:48 | https://www.zacks.com/stock/news/1880933/abbvie-s-abbv-qulipta-meets-chronic-migraine-study-endpoints | AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study. | AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-03-10 10:02:49 | https://seekingalpha.com/article/4494378-abbvie-is-still-cheap | AbbVie's cash flow and yield are finally getting some respect. | AbbVie Is Still Cheap | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-09 10:32:13 | https://www.zacks.com/stock/news/1879563/what-s-in-store-for-these-3-big-pharma-outperformers-in-2022 | J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond. | What's in Store for These 3 Big Pharma Outperformers in 2022? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-09 10:32:04 | https://www.zacks.com/stock/news/1879574/genmab-gmab-abbvie-lymphoma-candidate-gets-orphan-drug-tag | Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL. | Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-03-08 16:19:46 | https://www.gurufocus.com/news/1660569/blockbusters-from-bristolmyers-abbvie-losing-exclusivity | Of the $17 billion in annual sales that will be lost to copycat drugs this year, a Bristol-Myers Squibb Co. ( BMY , Financial) cancer medication is in line to take the biggest hit. | Blockbusters From Bristol-Myers, AbbVie Losing Exclusivity | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-03-08 16:03:02 | https://seekingalpha.com/article/4493846-abbvie-inc-abbv-presents-cowen-health-care-broker-conference-call-transcript | Abbvie, Inc. (ABBV) Presents at Cowen Health Care Broker Conference Call - (Transcript) | Abbvie, Inc. (ABBV) Presents at Cowen Health Care Broker Conference Call - (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-03-08 12:02:10 | https://www.zacks.com/stock/news/1879124/abbvie-abbv-outperforms-industry-this-year-so-far-what-next | AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential. | AbbVie (ABBV) Outperforms Industry This Year So Far: What Next? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-03-08 11:38:23 | https://seekingalpha.com/article/4493704-abbvie-inc-hunker-down-and-hedge-up | Global financial markets are going through extreme volatilities, with the market fluctuating more than 2% and the VIX index exceeding its 95% percentile. | AbbVie Inc.: Hunker Down And Hedge Up With Its 3.8% Dividend | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-03-05 14:00:34 | https://stockmarket.com/featured/4-defensive-stocks-to-watch-as-russia-ukraine-war-intensifies-2022-03-05 | Could these defensive stocks be your best defense against stock market volatility? | 4 Defensive Stocks To Watch As Russia-Ukraine War Intensifies | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-03-04 17:40:29 | https://www.gurufocus.com/news/1658312/face-it-tiny-evolus-is-primed-to-challenge-abbvies-botox | Small cap Evolus Inc. ( EOLS , Financial) is thinking big, and analysts agree the company can continue to make headway in the $2 billion U.S. market for aesthetics. The 10-year-old Newport Beach, California-based performance beauty company saw sales of its cosmetic neurotoxin Jeuveau jump 75% in 2021 to nearly $100 mil... | Face It, Tiny Evolus Is Primed to Challenge AbbVie's Botox | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-03-03 17:50:49 | https://www.gurufocus.com/news/1657669/abbvie-acquisition-strengthens-its-neuroscience-portfolio | The structure of AbbVie Inc.‘s ( ABBV , Financial) buyout of a clinical-stage biotechnology company this week may be indicative of the type of deals we're going to see more of. The Chicago-area company back-loaded the acquisition of privately held Syndesi Therapeutics, paying $130 million initially, with the opportunit... | AbbVie Acquisition Strengthens Its Neuroscience Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-03-03 10:53:00 | https://www.fool.com/investing/2022/03/03/is-this-dividend-king-a-buy-for-2022-and-beyond/ | AbbVie offers investors a market-beating dividend yield even as it trades near its all-time high. | Is This Dividend King a Buy for 2022 and Beyond? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2022-03-03 07:30:47 | https://www.forbes.com/sites/greatspeculations/2022/03/03/heres-why-humira-maker-is-a-better-bet-compared-to-johnson--johnson-stock/ | We think AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. | Here's Why Humira Maker Is A Better Bet Compared To Johnson & Johnson Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-03-02 08:47:00 | https://www.fool.com/investing/2022/03/02/has-the-market-correction-made-abbvie-stock-cheap/ | The stock is up so far this year. | Has the Market Correction Made AbbVie Stock Cheap? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-03-02 07:21:31 | https://247wallst.com/investing/2022/03/02/5-warren-buffett-stocks-are-very-safe-buys-now-and-pay-big-dependable-dividends/ | If any investor has stood the test of time, it is Warren Buffett. For years, the “Oracle of Omaha” has had a rock-star-like presence in the investing world. | 5 Warren Buffett Stocks Are Very Safe Buys Now and Pay Big Dependable Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-03-01 06:48:16 | https://247wallst.com/investing/2022/03/01/3-biopharma-stocks-that-analysts-have-grown-bearish-on/ | The S&P 500, Nasdaq and Dow Jones industrial average have all entered correction territory within the past month, and investors took the brunt of this. | 3 Biopharma Stocks That Analysts Have Grown Bearish On | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2022-02-24 11:22:00 | https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-to-present-data-from-its-leading-portfolio-of-eye-care-treatments-at-the-2022-american-glaucoma-society-ags-annual-meeting-301489901.html | NORTH CHICAGO, Ill., Feb. 24, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced new data to be presented from Allergan's leading portfolio of eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting being held in Nashville, TN and virtually from March 3-6. | Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-02-23 12:37:51 | https://investorplace.com/2022/02/7-high-yield-blue-chip-stocks-suitable-for-any-retiree/ | Income investments are great for volatile times, as investors dump technology stocks and seek steady dividends and capital gains. The post 7 High-Yield Blue-Chip Stocks Suitable for Any Retiree appeared first on InvestorPlace. | 7 High-Yield Blue-Chip Stocks Suitable for Any Retiree | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-21 10:53:00 | https://www.fool.com/investing/2022/02/21/abbvie-is-a-top-pick-in-an-uncertain-market/ | With the markets experiencing turmoil in 2022, this company can stabilize your portfolio. | AbbVie Is a Top Pick in an Uncertain Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-20 09:29:00 | https://www.fool.com/investing/2022/02/20/3-rock-solid-stocks-that-are-money-machines/ | These big companies should continue generating strong cash flow and paying great dividends for years to come. | 3 Rock-Solid Stocks That Are Money Machines | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-19 10:53:00 | https://www.fool.com/investing/2022/02/19/this-number-is-a-big-green-flag-for-abbvie-stock/ | Skyrizi is finally starting to show its revenue potential. | This Number Is a Big Green Flag for AbbVie Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-02-18 14:07:43 | https://www.youtube.com/watch?v=ypjmkDOBQic | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Home Depot, Cisco & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-18 08:38:00 | https://www.fool.com/investing/2022/02/18/abbvie-snags-fda-approval-for-another-indication-w/ | Immunology drug Skyrizi was authorized by the Food and Drug Administration to treat psoriatic arthritis. | AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2022-02-17 14:04:18 | https://www.forbes.com/sites/dividendchannel/2022/02/17/daily-dividend-report-humana-cisco-waste-connections-stanley-black--decker-abbvie/ | Daily Dividend Report: Humana, Cisco, Waste Connections, Stanley Black & Decker, AbbVie | Daily Dividend Report: Humana, Cisco, Waste Connections, Stanley Black & Decker, AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-17 05:55:00 | https://www.fool.com/investing/2022/02/17/abbvie-is-a-better-stock-than-you-might-think-here/ | Don't worry about Humira's impending loss of exclusivity in the U.S. | AbbVie Is a Better Stock Than You Might Think -- Here's Why | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-16 07:30:00 | https://www.fool.com/investing/2022/02/16/why-abbvie-might-be-poised-for-a-return-to-profita/ | Is now an optimal time to buy? | Why Abbvie Might Be Poised for a Return to Profitability | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-02-15 13:12:44 | https://www.gurufocus.com/news/1642988/buffett-still-likes-chevron-continues-to-sell-health-care | Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its fourth-quarter 13F on Monday. | Buffett Still Likes Chevron, Continues to Sell Health Care | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-15 10:55:44 | https://seekingalpha.com/article/4487076-which-etfs-should-investors-be-watching-now-favorite-ibb | Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB | Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Kiplinger | 2022-02-14 19:39:03 | https://www.kiplinger.com/investing/stocks/604219/stocks-warren-buffett-is-buying-and-selling-q4-2021 | Warren Buffett once again was a net seller of equities in the fourth quarter, slicing, slashing and outright exiting stakes across a series of sectors that have fallen out of his favor. But the Oracle of Omaha did pull off a few interesting buys in Q4, too. | 10 Stocks Warren Buffett Is Selling | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-02-14 16:23:15 | https://investorplace.com/2022/02/4-top-stock-trades-for-tuesday-se-abbv-td-car/ | Sea Ltd, AbbVie, Toronto Dominion Bank and Avis Budget were our top stock trades for Tuesday. Here's how the charts look now. | 4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-02-14 14:29:44 | https://investorplace.com/2022/02/7-dividend-aristocrats-that-could-outpace-this-volatile-market/ | Dividend aristocrats are companies that have raised dividend payments at least once a year for the past 25 years. The post 7 Dividend Aristocrats That Could Outpace This Volatile Market appeared first on InvestorPlace. | 7 Dividend Aristocrats That Could Outpace This Volatile Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-02-11 12:19:11 | https://www.zacks.com/stock/news/1866486/will-the-rally-of-these-5-big-drugmakers-continue-in-2022 | Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals. | Will the Rally of These 5 Big Drugmakers Continue in 2022? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-11 07:33:09 | https://seekingalpha.com/article/4486268-abbvie-portfolio-topper-try-it-youll-like-it | AbbVie routinely meets and slightly beats ambitious growth targets, as it demonstrated again in its Q4, 2021 earnings call. | AbbVie: Portfolio Topper - Try It You'll Like It | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-11 05:29:00 | https://www.fool.com/investing/2022/02/11/2-dividend-stocks-that-are-better-investments-than/ | Not only do they pay high yields, they also have plenty of growth opportunities on the horizon. | 2 Dividend Stocks That Are Better Investments Than AT&T | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-09 11:22:57 | https://seekingalpha.com/article/4485480-abbvie-superb-2021-paves-way-for-further-outperformance-in-2022 | AbbVie: Superb 2021 Paves Way For Further Outperformance In 2022 | AbbVie: Superb 2021 Paves Way For Further Outperformance In 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2022-02-09 03:33:30 | https://pulse2.com/abbvie-nyse-abbv-stock-why-the-price-increased/ | The stock price of AbbVie Inc (NYSE: ABBV) increased by 0.69% in the most recent trading session. This is why it happened. | AbbVie (ABBV) Stock: Why The Price Increased | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-08 11:15:00 | https://www.fool.com/investing/2022/02/08/3-top-healthcare-stocks-to-buy-for-february/ | Whether you're looking for growth or big dividends, the healthcare sector's got deals galore. | 3 Top Healthcare Stocks to Buy for February | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-05 08:35:00 | https://seekingalpha.com/article/4484556-abbvie-stock-get-in-on-this-investor-trifecta | AbbVie offers Growth Potential, High-Yield, and Strong Dividend Growth. The company has long been led by the #1 selling drug in the world in Humira, but they are now taking a more diversified approach. | AbbVie Stock: Get In On This Investor Trifecta | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-05 06:25:00 | https://www.fool.com/investing/2022/02/05/is-abbvie-stock-a-buy-now/ | The healthcare company just reported strong quarterly earnings. | Is AbbVie Stock a Buy Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-05 02:14:33 | https://seekingalpha.com/article/4484628-sdog-high-yield-good-value-questionable-quality | SDOG: High Yield, Good Value, Questionable Quality | SDOG: High Yield, Good Value, Questionable Quality | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Invezz | 2022-02-02 15:14:04 | https://invezz.com/news/2022/02/02/abbvie-tops-fourth-quarter-estimates-by-3/ | AbbVie (NYSE: ABBV) reports $3.31 EPS in the fourth quarter, which tops the $3.28 analyst estimate by $0.03. However, the company recorded $14.89 billion in revenue in the same quarter, a little less than the $14.95 billion consensus estimate. | AbbVie tops fourth-quarter estimates by 3% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-02 13:44:06 | https://seekingalpha.com/article/4483642-abbvie-inc-abbv-ceo-rick-gonzalez-on-q4-2021-results-earnings-call-transcript | AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q4 2021 Results - Earnings Call Transcript | AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q4 2021 Results - Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-02-02 13:04:13 | https://www.zacks.com/stock/news/1861400/abbvie-s-abbv-q4-earnings-surpass-estimates-sales-miss | AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. | AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.